CompletedPhase 2NCT00001563
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
Studying OBSOLETE: HIV-related Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Wyndham H Wilson, M.D.National Cancer Institute (NCI)
- Intervention
- Filgrastim(biological)
- Enrollment
- 39 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1997 – 2005
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00001563 on ClinicalTrials.govOther trials for OBSOLETE: HIV-related Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05231135A Registry Study on HIV-related LymphomaRotkreuzklinikum München gGmbH
- ACTIVE NOT RECRUITINGPHASE1NCT03220022Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasNational Cancer Institute (NCI)
See all trials for OBSOLETE: HIV-related Non-Hodgkin lymphoma →